Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)
China · Delayed Price · Currency is CNY 10.14
+0.16 (1.60%)
At close: May 8, 2026
SHE:301301 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,024 | 4,227 | 5,397 | 4,515 | 3,574 | 3,055 |
Other Revenue | 389.55 | 389.55 | 361.61 | 308.58 | 246.72 | 177.08 |
| 4,414 | 4,616 | 5,758 | 4,823 | 3,821 | 3,232 | |
Revenue Growth (YoY) | -20.21% | -19.83% | 19.38% | 26.24% | 18.21% | -11.44% |
Cost of Revenue | 3,314 | 3,290 | 3,680 | 3,343 | 2,890 | 2,637 |
Gross Profit | 1,100 | 1,326 | 2,078 | 1,480 | 930.89 | 595.07 |
Selling, General & Admin | 179.9 | 181.2 | 190.87 | 165.7 | 155.54 | 130.22 |
Research & Development | 84.48 | 102.49 | 77.73 | 55.26 | 35.38 | 32.95 |
Other Operating Expenses | 68.8 | 67.21 | 79.51 | 66.52 | 54.94 | 36.7 |
Operating Expenses | 334.65 | 354.59 | 341.43 | 293.98 | 260.12 | 198.27 |
Operating Income | 765.25 | 971.68 | 1,737 | 1,186 | 670.77 | 396.8 |
Interest Expense | -31.93 | -33.82 | -61.91 | -87.78 | -142.34 | -176.88 |
Interest & Investment Income | 3.62 | 4.66 | 7.38 | 16.18 | 5.21 | 9.2 |
Currency Exchange Gain (Loss) | -0.38 | -0.38 | 6.69 | 12.18 | 14.71 | -5.37 |
Other Non Operating Income (Expenses) | -12.49 | -5.39 | -5.83 | -3.74 | -0.64 | -0.95 |
EBT Excluding Unusual Items | 724.07 | 936.74 | 1,683 | 1,123 | 547.7 | 222.8 |
Gain (Loss) on Sale of Investments | -8.34 | -5.74 | -9.16 | -14.73 | -8.96 | 0.55 |
Gain (Loss) on Sale of Assets | 0.35 | 0.35 | - | 1.34 | - | 0.26 |
Asset Writedown | -1.39 | -1.39 | -1.25 | -1.28 | -0.68 | -5.79 |
Other Unusual Items | 12.7 | 8.73 | 2.46 | 9.25 | -50.43 | -83.74 |
Pretax Income | 727.39 | 938.69 | 1,675 | 1,118 | 487.63 | 134.08 |
Income Tax Expense | 137.23 | 170.34 | 274.74 | 177.15 | 76.11 | 22.73 |
Earnings From Continuing Operations | 590.16 | 768.35 | 1,400 | 940.56 | 411.52 | 111.35 |
Minority Interest in Earnings | 1.36 | 0.66 | -0.03 | -0 | 0 | -0 |
Net Income | 591.52 | 769.01 | 1,400 | 940.56 | 411.52 | 111.35 |
Net Income to Common | 591.52 | 769.01 | 1,400 | 940.56 | 411.52 | 111.35 |
Net Income Growth | -55.72% | -45.08% | 48.88% | 128.56% | 269.58% | -51.38% |
Shares Outstanding (Basic) | 2,261 | 2,262 | 2,223 | 2,239 | 1,960 | 1,856 |
Shares Outstanding (Diluted) | 2,261 | 2,262 | 2,223 | 2,239 | 1,960 | 1,856 |
Shares Change (YoY) | 1.58% | 1.76% | -0.75% | 14.28% | 5.59% | -7.21% |
EPS (Basic) | 0.26 | 0.34 | 0.63 | 0.42 | 0.21 | 0.06 |
EPS (Diluted) | 0.26 | 0.34 | 0.63 | 0.42 | 0.21 | 0.06 |
EPS Growth | -56.41% | -46.03% | 50.00% | 100.00% | 250.00% | -45.45% |
Free Cash Flow | 511.11 | 451.85 | 1,748 | 947.26 | 644.44 | 750.94 |
Free Cash Flow Per Share | 0.23 | 0.20 | 0.79 | 0.42 | 0.33 | 0.41 |
Dividend Per Share | 0.173 | 0.173 | 0.270 | 0.225 | 0.093 | - |
Dividend Growth | -35.93% | -35.93% | 20.00% | 141.94% | - | - |
Gross Margin | 24.92% | 28.73% | 36.09% | 30.69% | 24.37% | 18.41% |
Operating Margin | 17.34% | 21.05% | 30.16% | 24.59% | 17.56% | 12.28% |
Profit Margin | 13.40% | 16.66% | 24.32% | 19.50% | 10.77% | 3.45% |
Free Cash Flow Margin | 11.58% | 9.79% | 30.36% | 19.64% | 16.87% | 23.23% |
EBITDA | 1,342 | 1,542 | 2,278 | 1,730 | 1,217 | 919.79 |
EBITDA Margin | 30.41% | 33.39% | 39.57% | 35.87% | 31.85% | 28.46% |
D&A For EBITDA | 576.89 | 569.86 | 541.74 | 543.6 | 546.07 | 522.99 |
EBIT | 765.25 | 971.68 | 1,737 | 1,186 | 670.77 | 396.8 |
EBIT Margin | 17.34% | 21.05% | 30.16% | 24.59% | 17.56% | 12.28% |
Effective Tax Rate | 18.87% | 18.15% | 16.40% | 15.85% | 15.61% | 16.96% |
Revenue as Reported | 4,414 | 4,616 | 5,758 | 4,823 | 3,821 | 3,232 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.